# PHIBRO ANIMAL HEALTH CORP (PAHC) Informational only - not investment advice. CIK: 0001069899 SIC: 2834 Pharmaceutical Preparations SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2834 Pharmaceutical Preparations](/industry/2834/) Latest 10-K filed: 2025-08-27 SEC page: https://www.sec.gov/edgar/browse/?CIK=1069899 Filing source: https://www.sec.gov/Archives/edgar/data/1069899/000155837025011776/pahc-20250630x10k.htm ## Selected Fundamentals | Metric | Value | Unit | FY | Filed | | --- | ---: | --- | ---: | --- | | Revenue | 1296215000 | USD | 2025 | 2025-08-27 | | Net income | 48264000 | USD | 2025 | 2025-08-27 | | Assets | 1360900000 | USD | 2025 | 2025-08-27 | ## Financials Annual standardized facts from SEC companyfacts as of latest extracted filing date 2025-08-27. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001069899.json. Derived margins are computed from the extracted annual SEC facts. | Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | | | | | 800,354,000 | 833,350,000 | 942,261,000 | 977,889,000 | 1,017,679,000 | 1,296,215,000 | | Net income | 82,728,000 | 64,615,000 | 64,883,000 | 54,713,000 | 33,552,000 | 54,385,000 | 49,175,000 | 32,606,000 | 2,416,000 | 48,264,000 | | Operating income | 85,744,000 | 97,934,000 | 98,926,000 | 83,226,000 | 69,194,000 | 74,868,000 | 78,986,000 | 71,847,000 | 53,315,000 | 110,465,000 | | Gross profit | 239,032,000 | 248,243,000 | 266,879,000 | 264,624,000 | 256,882,000 | 271,377,000 | 285,400,000 | 298,237,000 | 313,092,000 | 399,942,000 | | Diluted EPS | 2.07 | 1.61 | 1.61 | 1.35 | 0.83 | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 | | Assets | 607,835,000 | 623,397,000 | 671,679,000 | 726,671,000 | 784,100,000 | 841,325,000 | 931,699,000 | 971,397,000 | 982,184,000 | 1,360,900,000 | | Liabilities | 517,355,000 | 472,240,000 | 486,725,000 | 510,656,000 | 595,896,000 | 602,796,000 | 669,257,000 | 688,888,000 | 725,543,000 | 1,075,218,000 | | Stockholders' equity | 90,480,000 | 151,157,000 | 184,954,000 | 216,015,000 | 188,204,000 | 238,529,000 | 262,442,000 | 282,509,000 | 256,641,000 | 285,682,000 | | Cash and cash equivalents | 33,605,000 | 56,083,000 | 29,168,000 | 57,573,000 | 36,343,000 | 50,212,000 | 74,248,000 | 41,281,000 | 70,613,000 | 68,039,000 | | Net margin | | | | | 4.19% | 6.53% | 5.22% | 3.33% | 0.24% | 3.72% | | Operating margin | | | | | 8.65% | 8.98% | 8.38% | 7.35% | 5.24% | 8.52% | ## Quarterly Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-05-06. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001069899.json. Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived. | Quarter | End date | Revenue | Net income | Diluted EPS | Method | | --- | --- | ---: | ---: | ---: | --- | | 2023-Q1 | 2022-09-30 | | | 0.10 | reported discrete quarter | | 2023-Q2 | 2022-12-31 | | | 0.18 | reported discrete quarter | | 2023-Q3 | 2023-03-31 | | | 0.25 | reported discrete quarter | | 2023-Q4 | 2023-06-30 | 255,049,000 | 11,498,000 | | derived Q4 = FY annual - nine-month YTD | | 2024-Q1 | 2023-09-30 | 231,349,000 | -8,015,000 | -0.20 | reported discrete quarter | | 2024-Q2 | 2023-12-31 | 249,943,000 | 1,274,000 | 0.03 | reported discrete quarter | | 2024-Q3 | 2024-03-31 | 263,223,000 | 8,405,000 | 0.21 | reported discrete quarter | | 2024-Q4 | 2024-06-30 | 273,164,000 | 752,000 | | derived Q4 = FY annual - nine-month YTD | | 2025-Q1 | 2024-09-30 | 260,432,000 | 6,975,000 | 0.17 | reported discrete quarter | | 2025-Q2 | 2024-12-31 | 309,261,000 | 3,185,000 | 0.08 | reported discrete quarter | | 2025-Q3 | 2025-03-31 | 347,825,000 | 20,880,000 | 0.51 | reported discrete quarter | | 2025-Q4 | 2025-06-30 | 378,697,000 | 17,224,000 | | derived Q4 = FY annual - nine-month YTD | | 2026-Q1 | 2025-09-30 | 363,893,000 | 26,527,000 | 0.65 | reported discrete quarter | | 2026-Q2 | 2025-12-31 | 373,910,000 | 27,459,000 | 0.67 | reported discrete quarter | | 2026-Q3 | 2026-03-31 | 383,543,000 | 24,024,000 | 0.59 | reported discrete quarter | ## Macro Cross-References - [CPIAUCSL](/indicator/CPIAUCSL/): Consumer Price Index for All Urban Consumers: All Items in U.S. City Average - [UNRATE](/indicator/UNRATE/): Unemployment Rate - [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate - [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private - [DFEDTARU](/indicator/DFEDTARU/): Federal Funds Target Range - Upper Limit - [DFEDTARL](/indicator/DFEDTARL/): Federal Funds Target Range - Lower Limit - [DGS3MO](/indicator/DGS3MO/): Market Yield on U.S. Treasury Securities at 3-Month Constant Maturity - [DGS2](/indicator/DGS2/): Market Yield on U.S. Treasury Securities at 2-Year Constant Maturity - [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity - [DGS30](/indicator/DGS30/): Market Yield on U.S. Treasury Securities at 30-Year Constant Maturity - [T10Y2Y](/indicator/T10Y2Y/): 10-Year Treasury Constant Maturity Minus 2-Year Treasury Constant Maturity - [CPILFESL](/indicator/CPILFESL/): Consumer Price Index for All Urban Consumers: All Items Less Food and Energy - [CPIUFDSL](/indicator/CPIUFDSL/): Consumer Price Index for All Urban Consumers: Food - [CPIENGSL](/indicator/CPIENGSL/): Consumer Price Index for All Urban Consumers: Energy - [CUSR0000SAH1](/indicator/CUSR0000SAH1/): Consumer Price Index for All Urban Consumers: Shelter - [PCEPI](/indicator/PCEPI/): Personal Consumption Expenditures: Chain-type Price Index - [PCEPILFE](/indicator/PCEPILFE/): Personal Consumption Expenditures Excluding Food and Energy: Chain-type Price Index - [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities - [T10YIE](/indicator/T10YIE/): 10-Year Breakeven Inflation Rate - [U6RATE](/indicator/U6RATE/): Total Unemployed, Plus All Marginally Attached Workers Plus Total Employed Part Time for Economic Reasons - [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm - [CIVPART](/indicator/CIVPART/): Labor Force Participation Rate - [EMRATIO](/indicator/EMRATIO/): Employment-Population Ratio - [UNEMPLOY](/indicator/UNEMPLOY/): Unemployed - [CE16OV](/indicator/CE16OV/): Employment Level - [ICSA](/indicator/ICSA/): Initial Claims - [JTSJOL](/indicator/JTSJOL/): Job Openings: Total Nonfarm - [JTSQUR](/indicator/JTSQUR/): Quits: Total Nonfarm - [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product - [A191RL1Q225SBEA](/indicator/A191RL1Q225SBEA/): Real Gross Domestic Product: Percent Change from Preceding Period - [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index - [TCU](/indicator/TCU/): Capacity Utilization: Total Index - [HOUST](/indicator/HOUST/): New Privately-Owned Housing Units Started: Total Units - [PERMIT](/indicator/PERMIT/): New Privately-Owned Housing Units Authorized in Permit-Issuing Places: Total Units - [RSAFS](/indicator/RSAFS/): Advance Retail Sales: Retail Trade - [PCE](/indicator/PCE/): Personal Consumption Expenditures - [DSPIC96](/indicator/DSPIC96/): Real Disposable Personal Income - [PSAVERT](/indicator/PSAVERT/): Personal Saving Rate - [M2SL](/indicator/M2SL/): M2 - [BOPGSTB](/indicator/BOPGSTB/): U.S. International Trade in Goods and Services: Balance - [MSPUS](/indicator/MSPUS/): Median Sales Price of Houses Sold for the United States - [HSN1F](/indicator/HSN1F/): New One Family Houses Sold: United States - [RHORUSQ156N](/indicator/RHORUSQ156N/): Homeownership Rate in the United States - [TTLCONS](/indicator/TTLCONS/): Total Construction Spending: Total Construction in the United States - [RRVRUSQ156N](/indicator/RRVRUSQ156N/): Rental Vacancy Rate in the United States - [TOTALSL](/indicator/TOTALSL/): Total Consumer Credit Owned and Securitized - [REVOLSL](/indicator/REVOLSL/): Revolving Consumer Credit Owned and Securitized - [DRCCLACBS](/indicator/DRCCLACBS/): Delinquency Rate on Credit Card Loans, All Commercial Banks - [GDP](/indicator/GDP/): Gross Domestic Product - [GPDI](/indicator/GPDI/): Gross Private Domestic Investment - [GCE](/indicator/GCE/): Government Consumption Expenditures and Gross Investment - [PCEC](/indicator/PCEC/): Personal Consumption Expenditures - [NETEXP](/indicator/NETEXP/): Net Exports of Goods and Services - [GFDEBTN](/indicator/GFDEBTN/): Federal Debt: Total Public Debt - [GFDEGDQ188S](/indicator/GFDEGDQ188S/): Federal Debt: Total Public Debt as Percent of Gross Domestic Product - [FYFSD](/indicator/FYFSD/): Federal Surplus or Deficit - [FGRECPT](/indicator/FGRECPT/): Federal Government Current Receipts - [FGEXPND](/indicator/FGEXPND/): Federal Government: Current Expenditures - [MANEMP](/indicator/MANEMP/): All Employees, Manufacturing - [USCONS](/indicator/USCONS/): All Employees, Construction - [USTRADE](/indicator/USTRADE/): All Employees, Retail Trade - [USFIRE](/indicator/USFIRE/): All Employees, Financial Activities - [USGOVT](/indicator/USGOVT/): All Employees, Government - [AWHAETP](/indicator/AWHAETP/): Average Weekly Hours of All Employees, Total Private - [DGORDER](/indicator/DGORDER/): Manufacturers' New Orders: Durable Goods - [NEWORDER](/indicator/NEWORDER/): Manufacturers' New Orders: Nondefense Capital Goods Excluding Aircraft - [BUSINV](/indicator/BUSINV/): Total Business Inventories - [EXPGS](/indicator/EXPGS/): Exports of Goods and Services - [IMPGS](/indicator/IMPGS/): Imports of Goods and Services - [IR](/indicator/IR/): Import Price Index (End Use): All Commodities - [PPIFIS](/indicator/PPIFIS/): Producer Price Index by Commodity: Final Demand ## Latest quarter (10-Q) Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1069899/000110465926056280/pahc-20260331x10q.htm Extracted between Part I Item 2 and the next Item 3/4 or Part II heading after HTML sanitization. Confidence: high Filing date: 2026-05-06 Report date: 2026-03-31 Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations Introduction Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” in Item 1A of our Annual Report and “Forward-Looking Statements.” Overview of our business Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. Our products help prevent, control and treat diseases, and support nutrition to help improve animal health and well-being. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries. Acquisition In April 2024, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’s medicated feed additive (“MFA”) portfolio, certain water-soluble products and related assets (the “Acquisition”). On October 31, 2024, the Company completed the Acquisition at a purchase price of approximately $297.5 million ($286.5 million, as adjusted, net of cash acquired). The Acquisition was funded by term loan borrowings under the 2024 Credit Agreement. Since the Acquisition, the product portfolio acquired has contributed $478.7 million to our overall net sales, of which $95.9 million and $77.0 million were recorded in the three months ended March 31, 2026 and 2025, and $270.5 million and $113.7 million were recorded in the nine months ended March 31, 2026 and 2025, respectively. Also included in the Acquisition were six manufacturing sites, comprised of four in the U.S., one in Italy and one in China. The results of operations of the Acquisition are included in our consolidated statements of operations from the date of acquisition and reported within the Animal Health segment. 2024 Credit Agreement In July 2024, we entered into a Credit Agreement (the “2024 Credit Agreement”) with a group of lenders. Initial borrowings were used to refinance all our outstanding debt, to pay fees and expenses of the transaction, and for ongoing working capital requirements and general corporate purposes. Borrowings under the Delayed Draw Term A-1 and A-2 Loans were used to finance the purchase price of the Acquisition. See “Notes to Consolidated Financial Statements — Debt — 2024 Credit Agreement” for additional information. On April 28, 2026, the 2024 Credit Agreement was amended to increase our borrowing capacity by expanding the Revolving Credit Commitments by $125.0 million, from $310.0 million to an aggregate commitment of $435.0 million. The expanded borrowing capacity provides the Company with enhanced operating flexibility. Fees of approximately $0.6 million were incurred to execute this amendment and will be amortized to interest expense through the maturity date of the Revolving Credit Commitments. ​ ​ ​ 26 Table of Contents Armed Conflicts Middle East Conflicts Since October 2023, Israel has been engaged in ongoing hostilities along its northern and southern borders, and tensions in the broader Middle East, including with Iran, remain elevated. The situation in the region is volatile, unpredictable, and subject to rapid escalation. We have three manufacturing sites in Israel. A manufacturing plant in Neot Hovav that produces active pharmaceutical ingredients for certain of our anticoccidial and antimicrobial products, a facility in Beit Shemesh that produces vaccines and a plant in Petah Tikvah that manufactures premix products and nutritional products. In addition, we have an office location near Tel Aviv in Airport City. As of March 31, 2026, we had approximately 520 employees located in Israel. We have confidence in our ability to meet our supply commitment to customers and maintain sufficient inventory to continue regional support. Our operations in Israel have navigated numerous challenging situations over the years. The continuation and/or escalation of conflicts in the region may trigger additional bans, economic and other sanctions, as well as broader military actions, which could include neighboring nations and their respective allies. The potential impact of the current conflicts, or escalation thereof, on our business is unclear but may include, without limitation, the possible disruption of our operations, particularly at our facilities in Israel, supply chain and logistics disruptions, personnel and raw material shortages, and other consequences, including as a result of the actions of, or disruption of the operations of, certain regulatory and governmental authorities and of certain of our suppliers, collaborative partners, licensees, manufacturing sites, distributors and customers. Our Israeli manufacturing facilities and local operations account for 17% of our consolidated assets as of March 31, 2026, and 16% of our consolidated net sales for the nine months ended March 31, 2026. Russia and Ukraine In response to the armed conflict between Russia and Ukraine that began in February 2022, we and our employees have provided support to Ukraine in the form of monetary donations, free products and humanitarian services. Our limited intent for the Russian market is to continue to provide medicines and vaccines, and related regulatory and technical support, to help existing customers combat disease challenges in the production of food animals on their farms. We have no production or direct distribution operations and no planned investments in Russia. Since the conflict began, the United States and other North Atlantic Treaty Organization (“NATO”) member states, as well as non-member states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises. The continuation or escalation of the conflict may trigger additional economic and other sanctions, as well as broader military conflict. The potential impacts of any resulting bans, sanctions, boycotts or broader military conflicts on our business are uncertain. The potential impacts could include supply chain and logistics disruptions, macroeconomic impacts resulting from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy as well as heightened cybersecurity threats. Our sales to Russia and Ukraine for the twelve months ended March 31, 2026 represented approximately 1% of consolidated net sales. We cannot know if the conflict could escalate and result in broader economic and security concerns that could adversely affect our business, financial condition, or results of operations. ​ 27 Table of Contents Macroeconomic developments ​ Macroeconomic developments, such as adverse economic conditions worldwide, international conflicts, or efforts of governments to stimulate or stabilize the economy or manage trade disputes, may adversely impact our business. For example, the U.S. government has instituted or proposed changes in trade policies that include the renegotiation or termination of existing trade agreements, the imposition of higher tariffs on imports into the United States, and other government regulations affecting trade between the United States and other countries. These measures could introduce supply chain inefficiencies, challenge current trade agreements with certain nations, and affect the cost and availability of materials critical to our products. Any such tariffs, if and when enacted, and any further legislation or actions taken by the U.S. government that restrict trade, such as additional tariffs, trade barriers, and other protectionist or retaliatory measures could adversely impact our ability to sell products and services in our markets. Countries may, in response to any U.S. actions, adopt retaliatory or other protectionist measures that could further limit our ability to offer our products and services. The ultimate impact of any tariffs will depend on various factors, including if any tariffs are ultimately implemented, the timing of implementation, and the amount, scope, and nature of the tariffs. In February 2026, the Supreme Court of the United States ruled that tariffs previously imposed under the International Emergency Economic Powers Act (“IEEPA”) were not authorized. In response to this ruling, we are pursuing the potential recovery of IEEPA tariffs previously paid and expect to submit claims through the administrative process administered by U.S. Customs and Border Protection for the refund of tariffs previously paid by the Company. The ruling did not address potential refunds, and therefore the ultimate availability, timing, and amount of the recovery of any potential refunds of these tariffs is highly uncertain and may be subject to further legal, regulatory, and administrative developments. Accordingly, the Company has not recognized any receivable or benefit related to these potential recoveries in its financial statements as of March 31, 2026 and will continue to monitor relevant developments and evaluate the recognition of such recoveries in future periods. We believe global population growth, the growth of the global middle class and the productivity improvements needed due to limitations of arable land and water supplies have supported and will continue to support growth of the animal health industry. Regulatory developments In April 2016, the Food and Drug Administration (“FDA”) began initial steps to withdraw approval of carbadox (the active ingredient in our Mecadox product) via a regulatory process known as a Notice of Opportunity for Hearing (“NOOH”), due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the FDA’s CVM inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method. In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the research and data that confirm the safety of carbadox. In November 2023, the FDA issued a final order to revoke the approved method for detecting carbadox residues. The FDA also provided notice in the Federal Register proposing to withdraw approval of all NADAs providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to req [Excerpt truncated for page length; source filing is linked above.] ## Latest 10-K MD&A Extracted between Item 7 and the next Item 7A/8 heading after HTML sanitization. Confidence: high Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations Introduction Our management’s discussion and analysis of financial condition and results of operations (“MD&A”) is provided to assist readers in understanding our performance, as reflected in the results of our operations, our financial condition and our cash flows. The following discussion summarizes the significant factors affecting our consolidated operating results, financial condition, liquidity and cash flows as of and for the periods presented. This MD&A should be read in conjunction with our consolidated financial statements and related notes thereto included under the section entitled “Financial Statements and Supplementary Data.” Our future results could differ materially from our historical performance as a result of various factors such as those discussed in “Risk Factors” and “Forward-Looking Statements and Risk Factors Summary.” Overview of our business Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. Our products help prevent, control and treat diseases, and support nutrition to help improve animal health and well-being. In addition to animal health and mineral nutrition products, we manufacture and market specific ingredients for use in the personal care, industrial chemical and chemical catalyst industries. We market approximately 800 product lines in approximately 90 countries to approximately 4,500 customers. Acquisition In April 2024, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’s medicated feed additive (“MFA”) portfolio, certain water-soluble products and related assets (the “Acquisition”). On October 31, 2024, the Company completed the Acquisition at a purchase price of approximately $297.5 million ($286.5 million, as adjusted, net of cash acquired), subject to certain further adjustments set forth in the Purchase Agreement. The Acquisition was funded by term loan borrowings under the 2024 Credit Agreement. The product portfolio acquired, which generated $407.6 million in revenue in 2023, is comprised of more than 37 product lines that are sold in approximately 80 countries. For the year ended June 30, 2025, this product portfolio contributed $208.2 million to our overall net sales. Also included in the Acquisition are six manufacturing sites, comprised of four in the U.S., one in Italy and one in China. The results of operations of the Acquisition are included in our consolidated statements of operations from the date of acquisition and reported within the Animal Health segment. 2024 Credit Agreement In July 2024, we entered into a Credit Agreement (the “2024 Credit Agreement”) with a group of lenders. Initial borrowings were used to refinance all our outstanding debt, to pay fees and expenses of the transaction, and for ongoing working capital requirements and general corporate purposes. Borrowings under the Delayed Draw Term A-1 and A-2 Loans were used to finance the purchase price of the Acquisition. See “Notes to Consolidated Financial Statements — Debt — 2024 Credit Agreement” for additional information. ​ 63 Table of Contents Armed conflicts Israel and Hamas On October 7, 2023, Hamas militants crossed into Israel from Gaza in a large-scale, surprise terrorist attack. Hamas terrorists invaded Israel, first firing rockets into the country and then carrying out attacks inflicting mass casualties with hundreds more taken hostage. In order to provide immediate assistance to the victims of the attacks and their families, we and our employees provided monetary donations that were distributed to charities that offered relief services, welfare, equipment, food and other necessities. Since the October 2023 attack, there have been continued and escalating hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen). Although a ceasefire was brokered between Israel and Hezbollah in November 2024, and in January 2025, and a temporary ceasefire went into effect between Israel and Hamas, hostilities in the region have recently resumed. The possibility of negotiations for renewed ceasefire agreements between Israel and Hamas, and Israel and Hezbollah remain uncertain and difficult to predict and until resolved, may continue to cause conflict in the region. We have three manufacturing sites in Israel. A manufacturing plant in Neot Hovav that produces active pharmaceutical ingredients for certain of our anticoccidial and antimicrobial products, a facility in Beit Shemesh that produces vaccines and a plant in Petah Tikvah that manufactures premix products and nutritional products. In addition, we have an office location near Tel Aviv in Airport City. As of June 30, 2025, we had approximately 500 employees located in Israel. While we initially had some disruption to our operations at the onset of the Israel-Hamas conflict, at the current time, we have confidence in our ability to meet our supply commitment to customers and maintain sufficient inventory to continue regional support. Iran has threatened to continue to attack Israel. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. While the situation surrounding the ongoing conflict remains fluid, our operations in Israel have navigated numerous challenging situations over the years. The resumption, prolonged continuation or escalation of this conflict may trigger bans, economic and other sanctions, as well as broader military conflict, which could include neighboring nations and their respective allies. The potential impact of the current conflict, or escalation thereof, on our business is unclear but may include, without limitation, the possible disruption of our operations, particularly at our facilities in Israel, supply chain and logistics disruptions, personnel and raw material shortages, and other consequences, including as a result of the actions of, or disruption of the operations of, certain regulatory and governmental authorities and of certain of our suppliers, collaborative partners, licensees, manufacturing sites, distributors and customers. Our Israeli manufacturing facilities and local operations account for 16% of our consolidated assets as of June 30, 2025, and 17% of our consolidated net sales for the twelve months ended June 30, 2025. Russia and Ukraine In response to the armed conflict between Russia and Ukraine that began in February 2022, we and our employees have provided support to Ukraine in the form of monetary donations, free products and humanitarian services. Our limited intent for the Russian market is to continue to provide medicines and vaccines, and related regulatory and technical support, to help existing customers combat disease challenges in the production of food animals on their farms. We have no production or direct distribution operations and no planned investments in Russia. Since the conflict began, the United States and other North Atlantic Treaty Organization (“NATO”) member states, as well as non-member states, announced targeted economic sanctions on Russia, including certain Russian citizens and enterprises. The continuation or escalation of the conflict may trigger additional economic and other sanctions, as well as broader military conflict. The potential impacts of any resulting bans, sanctions, boycotts or broader military conflicts on our business are uncertain. The potential impacts could include supply chain and logistics disruptions, macroeconomic impacts resulting from the exclusion of Russian financial institutions from the global banking system, volatility in foreign exchange rates and interest rates, inflationary pressures on raw materials and energy as well as heightened cybersecurity threats. Our sales to Russia and Ukraine for the twelve months ended June 30, 2025 represented approximately 1% of consolidated net sales. We cannot know if the conflict could escalate and result in broader economic and security concerns that could adversely affect our business, financial condition, or results of operations. 64 Table of Contents Industry growth We believe global population growth, the growth of the global middle class and the productivity improvements needed due to limitations of arable land and water supplies have supported and will continue to support growth of the animal health industry. Regulatory developments Our business depends heavily on a healthy and growing livestock industry. Some in the public perceive risks to human health related to the consumption of food derived from animals that utilize certain of our products, including certain of our MFA products. In particular, there is increased focus, in the United States and other countries, on the use of medically important antimicrobials. As defined by the FDA, medically important antimicrobials (“MIAs”) include classes that are prescribed in animal and human health and are listed in the Appendix of the FDA-CVM Guidance for Industry (GFI) 152. Our products that contain virginiamycin, oxytetracycline, neomycin, streptomycin, tiamulin, chlortetracycline, or sulfamethazine are classified by the FDA as medically important antimicrobials. In addition to the United States, the World Health Organization (WHO), the E.U., Australia and Canada have promulgated rating lists for antimicrobials that are used in veterinary medicine and that include certain of our products. The classification of our products as MIAs or similar listings may lead to a decline in the demand for and production of food products derived from animals that utilize our products and, in turn, demand for our products. Livestock producers may experience decreased demand for their products or reputational harm as a result of evolving consumer views of nutrition and health-related concerns, animal rights and other concerns. Any reputational harm to the livestock industry may also extend to companies in related industries, including us. In addition, campaigns by interest groups, activists and others with respect to perceived risks associated with the use of our products in animals, including position statements by livestock producers and their customers based on non-use of certain medicated products in livestock production, whether or not scientifically-supported, could affect public perceptions and reduce the use of our products. Those adverse consumer views related to the use of one or more of our products in animals could have a material adverse effect on our financial condition and results of operations. In April 2016, the FDA began initial steps to withdraw approval of carbadox (the active ingredient in our Mecadox product) via a regulatory process known as a Notice of Opportunity for Hearing (“NOOH”), due to concerns that certain residues from the product may persist in animal tissues for longer than previously determined. In the years following, Phibro has continued an ongoing process of responding collaboratively and transparently to the FDA’s CVM inquiries and has provided extensive and meticulous research and data that confirmed the safety of carbadox. In July 2020, the FDA announced it would not proceed to a hearing on the scientific concerns raised in the 2016 NOOH, consistent with the normal regulatory procedure, but instead announced that it was withdrawing the 2016 NOOH and issuing a proposed order to review the regulatory method for carbadox. Phibro reiterated the safety of carbadox and the appropriateness of the regulatory method and offered to work with the CVM to generate additional data to support the existing regulatory method or select a suitable alternative regulatory method. In March 2022, the FDA held a Part 15 virtual public hearing seeking data and information related to the safety of carbadox in which Phibro participated and again detailed the research and data that confirm the safety of carbadox. In November 2023, the FDA issued a final order to revoke the approved method for detecting carbadox residues. The FDA also provided notice in the Federal Register proposing to withdraw approval of all NADAs providing for use of carbadox in medicated swine feed and announcing an opportunity for Phibro to request a hearing on this proposal. This second action is based on CVM’s determination that there is no approved regulatory method to detect carbadox residues in the edible tissues of the treated swine. Phibro is continuing to defend swine producers’ ability to use Mecadox. We have requested a full evidentiary hearing on the merits before an administrative law judge. In January 2024, Phibro filed a lawsuit in the D.C. Federal District Court asking the court to invalidate the order which revoked the regulatory method for carbadox. Should we be unable to successfully defend the safety of the product, the loss of carbadox sales will have an adverse effect on our financial condition and results of operations. Sales of Mecadox (carbadox) for the year ended June 30, 2025 were approximately $20 million. As of the date of this Annual Report on Form 10-K, Mecadox continues to be available for use by swine producers. ​ 65 Table of Contents Macroeconomic developments, such as adverse economic conditions worldwide, international conflicts, or efforts of governments to stimulate or stabilize the economy or manage trade disputes, may adversely impact our business. For example, the Trump administration has instituted or proposed changes in trade policies that include the renegotiation or termination of existing trade agreements, the imposition of higher tariffs on imports into the United States, and other government regulations affecting trade between the United States and other countries. These measures could introduce supply chain inefficiencies, challenge current trade agreements with certain nations, and affect the cost and availability of materials critical to our products. Any such tariffs, if and when enacted, and any further legislation or actions taken by the U.S. federal government that restrict trade, such as additional tariffs, trade barriers, and other protectionist or retaliatory measures could adversely impact our ability to sell products and services in our markets. Countries may, in response to any U.S. actions, adopt retaliatory or other protectionist measures that could further limit our ability to offer our products and services. The ultimate impact of any tariffs will depend on various factors, including if any tariffs are ultimately implemented, the timing of implementation, and the amount, scope, and nature of the tariffs. See also “Business —  Compliance with Government Regulation  — United States — Carbadox”; and “Business — Compliance with Government Regulation — Global Policy and Guidance.” Our global sales of antibacterials, anticoccidials and other products were $646 million, $421 million and $387 million for the years ended June 30, 2025, 2024 and 2023, respectively. Competition The animal health industry is highly competitive. We believe many of our competitors are conducting R&D activities in areas served by our products and in areas in which we are developing products. Our competitors include stand-alone animal health businesses and the animal health businesses of large pharmaceutical companies. In addition to competition from established participants, there could be new entrants to the animal health medicines and vaccines industry in the future. Principal methods of competition vary depending on the region, species, product category or individual products, including reliability, reputation, quality, price, service and promotion to veterinary professionals and livestock producers. Foreign exchange We conduct operations in many areas of the world, involving transactions denominated in a variety of currencies. For the year ended June 30, 2025, we generated approximately 43% of our net sales from operations outside the United States. Although a portion of our revenues are denominated in various currencies, the selling prices of the majority of our sales outside the United States are referenced in U.S. dollars, and as a result, our revenues have not been significantly affected by currency movements. We are subject to currency risk to the extent that our costs are denominated in currencies other than those in which we earn revenues. We manufacture some of our major products in Brazil and Israel and production costs are largely denominated in local currencies, while the selling prices of the products are largely set in U.S. dollars. As such, we are exposed to changes in cost of goods sold resulting from currency movements and may not be able to adjust our selling prices to offset such movements. In addition, we incur selling and administrative expenses in various currencies and are exposed to changes in such expenses resulting from currency movements. For the year ended June 30, 2025, our expenses were not significantly affected by currency movements. Because we have transactions denominated in various currencies, changes in currency exchange rates have had, and will continue to have, an impact on our results of operations. ​ 66 Table of Contents Climate Adverse weather events and natural disasters may interfere with and negatively impact operations at our manufacturing sites, research and development facilities and offices, which could have a material adverse effect on our financial condition and results of operations, especially if the impact of an event or disaster is frequent or prolonged. Our operations, and the activities of our customers, could be disrupted by climate change. The physical changes caused by climate change may prompt changes in regulations or consumer preferences which in turn could have negative consequences for our and our customers’ businesses. Climate change may negatively impact our customers’ operations, particularly those in the livestock industry, through climate-related impacts such as increased air and water temperatures, rising water levels and increased incidence of disease in livestock. Potential physical risks from climate change may include altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and other natural disasters, rising sea levels and a rising heat index, any of which could cause negative impacts to our and our customers’ businesses. If such events affect our customers’ businesses, they may purchase fewer of our products, and our revenues may be negatively impacted. Climate driven changes could have a material adverse effect on our financial condition and results of operations. There has been a broad range of proposed and promulgated state, national and international regulations aimed at reducing the effects of climate change. Such regulations could result in additional costs to maintain compliance and additional income or other taxes. Climate change regulations continue to evolve, and it is not possible to accurately estimate potential future compliance costs. Product development initiatives Our future success depends on both the continued strength of our existing product portfolio and the advancement of our innovation pipeline. We are actively pursuing additional regulatory approvals for expanded claims, new species indications, and market access for our current products. These efforts also include cross-clearances that enable the concurrent use of our medicated products with other therapies. We maintain a robust pipeline of new products, developed through internal research and development (“R&D”), strategic joint ventures, and targeted licensing or acquisition opportunities. A significant portion of our R&D investment is directed toward product lifecycle management, which includes expanding indications, reformulating existing products, and developing new combinations to meet evolving customer needs and regulatory requirements. We are also investing in next-generation vaccine technologies and microbial solutions that address animal health, nutrition, and sustainability challenges across diverse sectors—including environmental, industrial, and agricultural applications. Strategic Initiatives in Progress Our current strategic initiatives include several projects: ● We continue to scale operations at our vaccine production facility in Sligo, Ireland, which began commercial poultry vaccine production in 2022. Plans are underway to expand into swine and cattle vaccines. ​ ● In fiscal year 2023, we launched a new vaccine facility in Guarulhos, Brazil, focused on autogenous vaccines for swine, poultry, and aquaculture. ​ ● Our microbial and bioproduct development programs are advancing, with applications spanning animal health, environmental resilience, and industrial performance. ​ ● In the companion animal space, our Rejensa® joint care supplement continues to gain market traction. Our pipeline includes a potential treatment for mitral valve disease in dogs, a novel pain management product, and two oral care formulations. ​ We remain committed to advancing innovation through both internal capabilities and external collaborations, ensuring that our product development strategy supports long-term growth and customer value. 67 Table of Contents Analysis of the consolidated statements of operations Summary Results of Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change For the Year Ended June 30 ​ 2025 2024 2023 2025 / 2024 2024/ 2023 ​ ​ ​ (in thousands, except per share amounts and percentages) Net sales ​ $ 1,296,215 $ 1,017,679 $ 977,889 $ 278,536 ​ 27 %   $ 39,790 4 % Gross profit ​ 399,942 ​ 313,092 ​ 298,237 ​ 86,850 ​ 28 %   14,855 5 % Selling, general and administrative expenses ​ 289,477 ​ 259,777 ​ 226,390 ​ 29,700 ​ 11 %   33,387 15 % Operating income ​ 110,465 ​ 53,315 ​ 71,847 ​ 57,150 ​ * ​ (18,532) (26) % Interest expense, net ​ 34,602 ​ 18,536 ​ 15,321 ​ 16,066 ​ 87 %   3,215 21 % Foreign currency losses, net ​ 7,870 ​ 23,863 ​ 2,455 ​ (15,993) ​ (67) %   21,408 * ​ Income before income taxes ​ 67,993 ​ 10,916 ​ 54,071 ​ 57,077 ​ * ​ (43,155) (80) % Provision for income taxes ​ 19,729 ​ 8,500 ​ 21,465 ​ 11,229 ​ * ​ (12,965) (60) % Net income ​ $ 48,264 ​ $ 2,416 ​ $ 32,606 ​ $ 45,848 ​ * ​ $ (30,190) (93) % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income per share ​ ​ ​ ​ ​ ​ Basic ​ $ 1.19 ​ $ 0.06 ​ $ 0.81 ​ $ 1.13 ​ ​ ​ ​ $ (0.75) ​ Diluted ​ $ 1.19 ​ $ 0.06 ​ $ 0.81 ​ $ 1.13 ​ ​ ​ ​ $ (0.75) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average number of shares outstanding ​ ​ ​ ​ ​ ​ Basic 40,515 ​ 40,504 ​ 40,504 ​ ​ ​ ​ Diluted ​ ​ 40,678 ​ ​ 40,523 ​ ​ 40,504 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Ratio to net sales ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross profit 30.9 %   30.8 %   30.5 %   ​ ​ ​ Selling, general and administrative expenses 22.3 %   25.5 %   23.2 %   ​ ​ ​ Operating income 8.5 %   5.2 %   7.3 %   ​ ​ ​ Income before income taxes 5.2 %   1.1 %   5.5 %   ​ ​ ​ Net income 3.7 %   0.2 %   3.3 %   ​ ​ ​ Effective tax rate 29.0 %   77.9 %   39.7 %   ​ ​ ​ Certain amounts and percentages may reflect rounding adjustments. * Calculation not meaningful Changes in net sales from period to period primarily result from changes in volumes and average selling prices. Although a portion of our net sales is denominated in various currencies, the selling prices of the majority of our sales outside the United States are referenced in U.S. dollars, and as a result, currency movements have not significantly affected our revenues. Our effective income tax rate has varied from period to period and from the federal statutory rate, due to the mix of taxable profits in various jurisdictions; changes in tax rates from period to period, including changes in income tax legislation in the United States and various international jurisdictions; and the effects of changes in uncertain tax positions and valuation allowances. Our future effective income tax rate will vary due to the relative amounts of taxable income in various jurisdictions, future changes in tax rates and legislation and other factors. We expect to repatriate approximately $5.0 million of international earnings, which will be subject to applicable non-U.S. withholding and related taxes, net of reductions in U.S. income taxes. We intend to continue to reinvest indefinitely all other undistributed earnings of our foreign subsidiaries where we could be subject to applicable non-U.S. withholding and related taxes if amounts are repatriated to the U.S. See “Notes to Consolidated Financial Statements — Income Taxes” for additional information. 68 Table of Contents Net sales, Adjusted EBITDA and reconciliation of GAAP net income to Adjusted EBITDA We report Net sales and Adjusted EBITDA by segment to understand the operating performance of each segment. This enables us to monitor changes in net sales, costs and other actionable operating metrics at the segment level. See “— General description of non-GAAP financial measures” for descriptions of EBITDA and Adjusted EBITDA. Certain of our costs and assets are not directly attributable to a segment or segments, and we refer to these items as Corporate. We do not allocate Corporate costs or assets to the other segments because they are not used to evaluate the segments’ operating results or financial position. Corporate costs include certain costs related to executive management, information technology, legal, finance, human resources and business development. Segment net sales and Adjusted EBITDA: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change For the Year Ended June 30 2025 2024 2023 2025 / 2024 2024 / 2023 Net sales ​ (in thousands, except percentages) MFAs and other ​ $ 646,354 ​ $ 420,959 ​ $ 387,349 ​ $ 225,395 54 %   $ 33,610 9 % Nutritional specialties ​ 179,289 ​ 164,671 ​ 172,504 ​ 14,618 9 %   (7,833) (5) % Vaccines ​ 137,153 ​ 120,852 ​ 99,998 ​ 16,301 13 %   20,854 21 % Animal Health ​ 962,796 ​ 706,482 ​ 659,851 ​ 256,314 36 %   46,631 7 % Mineral Nutrition ​ 253,240 ​ 243,663 ​ 242,656 ​ 9,577 4 %   1,007 0 % Performance Products ​ 80,179 ​ 67,534 ​ 75,382 ​ 12,645 19 %   (7,848) (10) % Total ​ $ 1,296,215 ​ $ 1,017,679 ​ $ 977,889 ​ $ 278,536 27 %   $ 39,790 4 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA ​ ​ ​ ​ ​ ​ Animal Health ​ $ 222,260 ​ $ 145,606 ​ $ 136,139 ​ $ 76,654 53 %   $ 9,467 7 % Mineral Nutrition ​ 20,836 ​ 16,449 ​ 17,417 ​ 4,387 27 %   (968) (6) % Performance Products ​ 10,547 ​ 7,662 ​ 9,346 ​ 2,885 38 %   (1,684) (18) % Corporate ​ (69,959) ​ (58,480) ​ (50,149) ​ (11,479) 20 %   (8,331) 17 % Total ​ $ 183,684 ​ $ 111,237 ​ $ 112,753 ​ $ 72,447 65 %   $ (1,516) (1) % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA as a percentage of segment net sales ​ ​ ​ ​ ​ ​ Animal Health ​ 23.1 %   20.6 %   20.6 %   ​ ​ Mineral Nutrition ​ 8.2 %   6.8 %   7.2 %   ​ ​ Performance Products ​ 13.2 %   11.3 %   12.4 %   ​ ​ Corporate(1) ​ (5.4) %   (5.7) %   (5.1) %   ​ ​ Total(1) ​ 14.2 %   10.9 %   11.5 %   ​ ​ (1) Reflects ratio to total net sales. Certain amounts and percentages may reflect rounding adjustments. * Calculation not meaningful 69 Table of Contents A reconciliation of net income, as reported under GAAP, to Adjusted EBITDA: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change For the Year Ended June 30 2025 2024 2023 2025/ 2024 2024/ 2023 ​ ​ (in thousands, except percentages) Net income ​ $ 48,264 ​ $ 2,416 ​ $ 32,606 ​ $ 45,848 * ​ $ (30,190) (93) % Interest expense, net ​ 34,602 ​ 18,536 ​ 15,321 ​ 16,066 87 %   3,215 21 % Provision for income taxes ​ 19,729 ​ 8,500 ​ 21,465 ​ 11,229 * ​ (12,965) (60) % Depreciation and amortization ​ 45,605 ​ 36,178 ​ 34,012 ​ 9,427 26 %   2,166 6 % EBITDA ​ 148,200 ​ 65,630 ​ 103,404 ​ 82,570 * ​ (37,774) (37) % Acquisition-related cost of goods sold ​ 5,679 ​ 521 ​ — ​ 5,158 * ​ 521 * ​ Acquisition-related transaction costs ​ ​ 13,322 ​ ​ 6,405 ​ ​ — ​ ​ 6,917 * ​ 6,405 * ​ Pension settlement cost ​ ​ — ​ ​ 10,674 ​ ​ — ​ ​ (10,674) ​ * ​ ​ 10,674 ​ * ​ Brazil employment taxes ​ ​ — ​ ​ 4,202 ​ ​ — ​ ​ (4,202) ​ * ​ ​ 4,202 ​ * ​ Stock-based compensation ​ 717 ​ 475 ​ — ​ 242 51 %   475 * ​ Phibro Forward income growth initiatives implementation costs - cost of goods sold (1) ​ ​ 3,798 ​ ​ — ​ ​ — ​ ​ 3,798 ​ * ​ ​ — ​ * ​ Phibro Forward income growth initiatives implementation costs - SG&A (1) ​ 6,978 ​ 366 ​ — ​ 6,612 * ​ 366 * ​ Insurance proceeds ​ ​ (2,880) ​ ​ (899) ​ ​ — ​ ​ (1,981) * ​ (899) * ​ Environmental remediation costs ​ ​ — ​ ​ — ​ ​ 6,894 ​ ​ — * ​ ​ (6,894) * ​ Foreign currency losses, net ​ 7,870 ​ 23,863 ​ 2,455 ​ (15,993) (67) %   21,408 * ​ Adjusted EBITDA ​ $ 183,684 ​ $ 111,237 ​ $ 112,753 ​ $ 72,447 65 %   $ (1,516) (1) % (1) Phibro Forward is a company-wide initiative focused on unlocking additional areas of revenue growth and cost savings. For the year ended June 30, 2025, this included $5.3 million for non-cash asset write-offs, of which $3.8 million was recorded within cost of goods sold, and $1.5 million was recorded within selling, general, and administrative expenses, related to the closure of an immaterial business within the Animal Health segment. Certain amounts and percentages may reflect rounding adjustments. * Calculation not meaningful Comparison of the years ended June 30, 2025 and 2024 Net sales Net sales of $1,296.2 million for the year ended June 30, 2025 increased $278.5 million, or 27%, as compared to the year ended June 30, 2024. Animal Health increased $256.3 million, while Mineral Nutrition and Performance Products sales increased $9.6 million and $12.6 million, respectively. Animal Health Net sales of $962.8 million for the year ended June 30, 2025 increased $256.3 million, or 36%. Net sales of MFAs and other increased $225.4 million, or 54%, due to incremental revenues of $208.2 million from the Zoetis MFA portfolio acquired on October 31, 2024, increased demand for our MFAs in international regions, and higher demand for processing aids used in the ethanol fermentation industry. Net sales of nutritional specialty products increased $14.6 million, or 9%, primarily due to increased domestic demand for dairy and higher sales of microbial and companion animal products. Net sales of vaccines increased $16.3 million, or 13%, primarily due to continued growth of poultry products in Latin America and increased domestic demand for swine products. Mineral Nutrition Net sales of $253.2 million for the year ended June 30, 2025 increased $9.6 million, or 4%, primarily due to an increase in demand for copper and trace minerals. 70 Table of Contents Performance Products Net sales of $80.2 million for the year ended June 30, 2025 increased $12.6 million, or 19%, as a result of higher demand for the ingredients used in personal care products. Gross profit Gross profit of $399.9 million for the year ended June 30, 2025 increased $86.9 million, or 28%, as compared to the year ended June 30, 2024. Gross margin increased 10 basis points to 30.9% of net sales for the year ended June 30, 2025 as compared to 30.8% for the year ended June 30, 2024. The comparison to the prior year included $3.8 million of current period inventory write-offs attributable to the closure of an immaterial business and a net increase of $5.2 million for acquisition-related cost of goods sold related to purchase accounting adjustments for acquisitions. Excluding these items, gross profit increased $95.8 million, or 30.6%, and gross margin increased 80 basis points to 31.6% of net sales due to increased sales, an increase in average selling prices, and a favorable impact of foreign currency exchange rates, partially offset by higher distribution costs. Animal Health gross profit, excluding the inventory write-offs and purchase accounting adjustment discussed above, increased $86.9 million due to higher sales volume, higher average selling prices, and a favorable impact of foreign currency exchange rates, partially offset by higher distribution costs. Mineral Nutrition gross profit increased $5.1 million, driven by higher average selling prices. Performance Products gross profit increased $3.8 million, driven by increased sales volume. Selling, general and administrative expenses SG&A expenses of $289.5 million for the year ended June 30, 2025 increased $29.7 million, or 11%, as compared to the year ended June 30, 2024. SG&A for the year ended June 30, 2025 included $13.3 million for acquisition-related costs, $7.0 million of costs associated with Phibro Forward income growth initiatives, and $0.7 million in stock-based compensation expense, partially offset by $2.9 million related to an insurance settlement gain. SG&A for the year ended June 30, 2024 included a $10.7 million pension settlement charge, a $4.2 million cost for an unfavorable litigation result related to Brazil employment taxes, $6.4 million for acquisition-related costs, $0.5 million of stock-based compensation expense, and $0.4 million of costs associated with Phibro Forward income growth initiatives, partially offset by a $0.9 million insurance settlement gain. Excluding these items, SG&A increased $32.8 million, or 14%. Animal Health SG&A increased $20.5 million, primarily due to an increase in employee-related costs due in part to incremental headcount added as part of the Acquisition and new product launches in Brazil. Mineral Nutrition and Performance Products SG&A each increased by $0.4 million due to an increase in employee-related costs. Corporate expenses increased $11.5 million due to higher incentive-related employee costs and strategic investments. Interest expense, net Interest expense, net of $34.6 million for the year ended June 30, 2025 increased $16.1 million, or 87%, as compared to the year ended June 30, 2024, due to higher debt levels associated with the financing of the Acquisition and costs associated with the refinancing of the Company’s debt. Foreign currency losses, net Foreign currency losses, net for the year ended June 30, 2025 were $7.9 million, as compared to net losses of $23.9 million for the year ended June 30, 2024. Current period losses were driven by fluctuations in certain currencies relative to the U.S. dollar, most prominently, in the Israeli New Shekel, the Brazil Real and the Argentine Peso. Prior year period losses were driven in large part by a major devaluation in the Argentine Peso and the weakening of the Brazilian Real. ​ 71 Table of Contents Provision for income taxes The provision for income taxes was $19.7 million and $8.5 million for the years ended June 30, 2025 and 2024, respectively. The effective income tax rate was 29.0% and 77.9% for the years ended June 30, 2025 and 2024, respectively. The effective tax rate for the year ended June 30, 2025 was higher than our statutory rate of 21% primarily due to withholding taxes on planned repatriations and the impact of Global Intangible Low-Tax Income (“GILTI”) on tax expense, partially offset by the impact of foreign tax credits. The provision for income taxes for the year ended June 30, 2025 was also impacted by various other items, including (i) certain non-deductible write-offs in connection with the closure of an immaterial business included as part of the Phibro Forward initiatives, (ii) various items with lower tax benefits, most prominently, foreign currency losses and stock-based compensation expense, (iii) a $0.9 million expense from changes in uncertain tax positions related to prior years, and (iv) $0.4 million expense for withholding taxes related to dividends received from an international affiliate. The effective income tax rate without these items would have been 25.0% for the year ended June 30, 2025. The effective income tax rate for the year ended June 30, 2024 was unfavorably affected by the proportionally greater effect of certain items such as GILTI taxes when compared with reduced pre-tax income. The provision for income taxes for the year ended June 30, 2024 was also impacted by various other items, including (i) a $2.8 million expense for applicable non-U.S. withholding and related taxes, net of reductions in U.S. income taxes, related to the planned repatriation of approximately $80.0 million of international earnings in preparation for the Acquisition, (ii) a $1.2 million benefit related to the determination of whether a foreign tax is eligible for a U.S. foreign tax credit related to our fiscal year 2023, based on IRS guidance provided subsequent to June 30, 2023, (iii) a $1.2 million benefit related to the release of certain valuation allowances on non-U.S. companies, (iv) a $1.6 million expense from changes in uncertain tax positions related to prior years and certain other items, and (v) various items with lower tax benefits, most prominently, foreign currency losses and acquisition-related transaction costs. The effective income tax rate without these items would have been 26.9% for the year ended June 30, 2024. We record the GILTI-related aspects of comprehensive U.S. income tax legislation as a period expense. The provision for income taxes for the years ended June 30, 2025 and 2024 included $3.2 million and $2.0 million, respectively, of federal tax expense from the effects of GILTI. Our effective income tax rate included 4.7% and 18.3% related to GILTI income tax expense for the years ended June 30, 2025 and 2024, respectively. Net income Net income of $48.3 million for the year ended June 30, 2025 increased $45.8 million, as compared to net income of $2.4 million for the year ended June 30, 2024. Operating income increased $57.2 million, driven by higher gross profit, partially offset by higher SG&A of $29.7 million, which included net increases of $6.9 million and $6.6 million in acquisition-related costs and costs related to Phibro Forward income growth initiatives, respectively. Interest expense, net increased $16.1 million due to higher debt levels and costs associated with the refinancing of the Company’s debt. Foreign currency losses, net decreased $16.0 million. Income tax expense increased $11.2 million. Comparison of the years ended June 30, 2024 and 2023 For a comparison of our results of operations for the years ended June 30, 2024 and 2023, and an analysis of our financial condition, liquidity and capital resources for the year ended June 30, 2024, see “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended June 30, 2024, filed with the SEC on August 28, 2024. ​ 72 Table of Contents Adjusted net income and adjusted diluted earnings per share We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. See “—General description of non-GAAP financial measures” for more information. A reconciliation of net income, as reported under GAAP, to adjusted net income is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change For the Year Ended June 30 2025 2024 2023 ​ 2025/ 2024 2024/ 2023 ​ ​ ​ ​ (in thousands, except per share amounts and percentages) ​ Reconciliation of GAAP Net Income to Adjusted Net Income ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income ​ $ 48,264 ​ $ 2,416 ​ $ 32,606 ​ $ 45,848 * %   $ (30,190) ​ (93) % Adjustments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related items, net of income tax (1) ​ 20,057 ​ 13,063 ​ 6,959 ​ 6,994 54 % 6,104 ​ 88 % Certain significant items, net of income tax (1) ​ ​ 8,878 ​ ​ 11,420 ​ ​ 4,929 ​ ​ (2,542) (22) % ​ 6,491 ​ * ​ Foreign currency losses, net of income tax (1) ​ 6,366 ​ 19,429 ​ 2,936 ​ (13,063) (67) % 16,493 ​ * ​ Certain income tax items (1) ​ 1,375 ​ 2,035 ​ 1,533 ​ (660) (32) % 502 ​ 33 % Total adjustments, net of income tax ​ ​ 36,676 ​ ​ 45,947 ​ ​ 16,357 ​ ​ (9,271) ​ (20) % ​ 29,590 ​ * ​ Adjusted net income ​ $ 84,940 ​ $ 48,363 ​ $ 48,963 ​ $ 36,577 76 % $ (600) ​ (1) % ​ (1) See table titled “Items Excluded from Adjusted Net Income” below for further details. A reconciliation of reported diluted earnings per share (EPS), as reported under GAAP, to non-GAAP adjusted diluted EPS is: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change ​ For the Year Ended June 30 2025 2024 2023 ​ 2025/ 2024 2024/ 2023 ​ ​ ​ ​ (in thousands, except per share amounts and percentages) ​ Reconciliation of GAAP diluted EPS to Adjusted diluted EPS ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ GAAP EPS, diluted ​ $ 1.19 ​ $ 0.06 ​ $ 0.81 ​ $ 1.13 * % $ (0.75) ​ (93) % Adjustments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related items, net of income tax ​ 0.49 ​ 0.32 ​ 0.17 ​ 0.17 53 % 0.15 ​ 88 % Certain significant items, net of income tax ​ 0.22 ​ 0.28 ​ 0.12 ​ (0.06) (21) % 0.16 ​ * ​ Foreign currency losses, net of income tax ​ 0.16 ​ 0.48 ​ 0.07 ​ (0.32) (67) % 0.41 ​ * ​ Certain income tax items ​ 0.03 ​ 0.05 ​ 0.04 ​ (0.02) (40) % 0.01 ​ 25 % Adjustments EPS, diluted ​ ​ 0.90 ​ ​ 1.13 ​ ​ 0.40 ​ ​ (0.23) ​ (20) % ​ 0.73 ​ * ​ Adjusted EPS, diluted ​ $ 2.09 ​ $ 1.19 ​ $ 1.21 ​ $ 0.90 76 % $ (0.02) ​ (2) % ​ ​ 73 Table of Contents Items excluded from adjusted net income consisted of: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended June 30 ​ 2025 2024 2023 ​ ​ ​ (in thousands) Items Excluded from Adjusted Net Income ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related items ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquisition-related intangible amortization in cost of goods sold ​ $ 5,468 ​ $ 6,675 ​ $ 6,651 Acquisition-related cost of goods sold ​ 5,679 ​ 521 ​ — Acquisition-related intangible amortization in SG&A ​ ​ 2,375 ​ 2,986 ​ 3,045 Acquisition-related transaction costs in SG&A ​ ​ 13,322 ​ 6,405 ​ — Acquisition-related items - income taxes ​ ​ (6,787) ​ ​ (3,524) ​ ​ (2,737) Total acquisition-related items, net of income taxes ​ 20,057 ​ 13,063 ​ 6,959 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Certain significant items ​ ​ ​ ​ ​ ​ ​ ​ ​ Pension settlement cost ​ ​ — ​ 10,674 ​ — Brazil employment taxes ​ ​ — ​ 4,202 ​ — Stock-based compensation ​ ​ 717 ​ 475 ​ — Phibro Forward income growth initiatives implementation costs - cost of goods sold ​ ​ 3,798 ​ 366 ​ — Phibro Forward income growth initiatives implementation costs - SG&A ​ ​ 6,978 ​ ​ — ​ ​ — Insurance proceeds ​ ​ (2,880) ​ (899) ​ — Refinancing expense ​ ​ 1,960 ​ ​ — ​ ​ — Environmental remediation costs ​ ​ — ​ — ​ 6,894 Certain items - income taxes ​ ​ (1,695) ​ ​ (3,398) ​ ​ (1,965) Total certain items, net of income taxes ​ ​ 8,878 ​ ​ 11,420 ​ ​ 4,929 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign currency losses, net ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign currency losses, net ​ ​ 7,870 ​ 23,863 ​ 2,455 Foreign currency losses, net - income taxes ​ ​ (1,504) ​ ​ (4,434) ​ ​ 481 Total foreign currency losses, net, net of income taxes ​ ​ 6,366 ​ ​ 19,429 ​ ​ 2,936 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Certain income tax items ​ ​ ​ ​ ​ ​ ​ ​ ​ Non-U.S. withholding and related taxes, net, on planned repatriation ​ ​ — ​ ​ 2,828 ​ ​ — Foreign tax credit regulations ​ ​ — ​ ​ (1,223) ​ ​ 1,223 Change in valuation allowance ​ ​ — ​ ​ (1,204) ​ ​ — Changes in uncertain tax positions and certain other items ​ ​ 1,375 ​ ​ 1,634 ​ ​ 310 Total certain income tax items ​ ​ 1,375 ​ ​ 2,035 ​ ​ 1,533 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total adjustments, net of income taxes ​ $ 36,676 ​ $ 45,947 ​ $ 16,357 ​ Analysis of financial condition, liquidity and capital resources Net (decrease) increase in cash and cash equivalents was: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change For the Year Ended June 30 2025 2024 2023 2025/ 2024 2024/ 2023 ​ ​ (in thousands) Cash provided (used) by: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating activities ​ $ 80,124 ​ $ 87,594 ​ $ 13,310 ​ $ (7,470) ​ $ 74,284 Investing activities ​ (288,688) ​ (48,194) ​ (74,018) ​ (240,494) ​ 25,824 Financing activities ​ 207,134 ​ (6,768) ​ 26,987 ​ 213,902 ​ (33,755) Effect of exchange-rate changes on cash and cash equivalents ​ (1,144) ​ (3,300) ​ 754 ​ 2,156 ​ (4,054) Net (decrease) increase in cash and cash equivalents ​ $ (2,574) ​ $ 29,332 ​ $ (32,967) ​ $ (31,906) ​ $ 62,299 ​ 74 Table of Contents Operating activities Operating activities provided $80.1 million of net cash for the year ended June 30, 2025. Cash provided by net income, adjusted for the non-cash items, including depreciation and amortization, was $101.7 million. Cash used in the ordinary course of business from changes in operating assets and liabilities, net of the impact of the net assets acquired from the Acquisition, was $21.6 million. Accounts receivable used $55.2 million of cash due to higher sales. Inventories used $44.3 million of cash due to increased quantities on hand due to timing of inventory purchases and forecasted future demand. Accounts payable provided $45.6 million of cash due to timing of purchases and payments. Accrued expenses and other liabilities provided cash of $47.2 million, primarily due to timing of incurrence. Operating activities provided $87.6 million of net cash for the year ended June 30, 2024. Cash provided by net income, adjusted for non-cash items, including depreciation and amortization, was $54.5 million. Cash provided in the ordinary course of business from changes in operating assets and liabilities and other items was $33.1 million. Accounts receivable used $8.7 million of cash due to sales growth, partially offset by an improvement in days sales outstanding. Inventory provided $2.6 million of cash due to a decrease in quantities on hand, offset by increased raw materials and production costs. Other current assets provided $11.0 million due to timing of tax payments in international regions. Accounts payable provided $12.0 million of cash due to timing of purchases and payments. Accrued expenses and other liabilities provided cash of $12.2 million, primarily due to increased employee-related liabilities and accrued transaction costs. Investing activities Investing activities used $288.7 million of net cash for the year ended June 30, 2025, which included the purchase price paid for the Acquisition of $286.5 million, net of cash acquired. Capital expenditures were $38.3 million, as we continued to invest in expanding production capacity and productivity improvements. Purchases of our short-term investments used $14.0 million in cash, and maturities of our short-term investments provided $49.0 million in cash. Investing activities used $48.2 million of net cash for the year ended June 30, 2024. Capital expenditures were $41.2 million, related primarily to continued investments in expanded production capacity and productivity improvements, Net purchases and maturities of short-term investments used $4.0 million in cash. We acquired a business for $3.3 million, net of cash acquired. Other investing activities provided $0.3 million of cash. Financing activities Financing activities provided $207.1 million of net cash for the year ended June 30, 2025 and reflect the impact of the refinancing of our debt portfolio in July 2024 and the financing of the Acquisition. Proceeds of $300.0 million from the refinancing, as well as revolving credit facility borrowings were used to pay the remaining principal balances of the then outstanding debt of $313.1 million, and we used the proceeds of $350.0 million in term loan borrowings to finance the purchase price of the Acquisition. Net revolver payments on our credit facilities used $89.0 million in cash. We paid $11.9 million in scheduled quarterly principal payments on long-term debt during the year ended June 30, 2025. We also paid $10.4 million in debt issuance costs related to the refinancing and $19.4 million in dividends to holders of our Class A common stock and Class B common stock. Financing activities used $6.8 million of net cash for the year ended June 30, 2024. Net borrowings on our previous revolving credit facility provided $35.0 million in cash. We paid $22.3 million in scheduled long-term debt maturities. We paid $19.4 million in dividends to holders of our Class A common stock and Class B common stock. 75 Table of Contents Liquidity and capital resources We believe our cash on hand, operating cash flows and financing arrangements, including the availability of borrowings under the 2024 Credit Facility, will be sufficient to support our ongoing cash needs. We have considered the current and potential future effects of the macroeconomic market conditions in the financial markets. At this time, we expect adequate liquidity for at least the next twelve months. Aggregate maturities of long-term debt under the 2024 Credit Agreement are: ​ ​ ​ ​ ​ ​ ​ For the Years Ending June 30 ​ ​ Annual Maturities ​ ​ Interest Payments 2026 ​ $ 16,250 ​ $ 45,467 2027 ​ ​ 25,025 ​ ​ 44,231 2028 ​ ​ 25,025 ​ ​ 42,665 2029 ​ ​ 25,025 ​ ​ 41,098 2030 ​ ​ 325,549 ​ ​ 21,139 Thereafter ​ ​ 308,251 ​ ​ 20,629 Total ​ $ 725,125 ​ $ 215,229 ​ For purposes of estimating future interest payments until maturity, we assume long-term debt decreases in accordance with the scheduled amortization payments, the outstanding balance of the 2024 Revolver continues unchanged, the September 2024 and March 2025 interest rate swap agreements remain in place through their maturity dates, and future interest rates are the same as the rates at June 30, 2025. We can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements. We believe we will be able to comply with the terms of the covenants under the 2024 Credit Facilities based on our operating plan. In the event of adverse operating results and/or violation of covenants under the facilities, there can be no assurance we would be able to obtain waivers or amendments. Other risks to our meeting future funding requirements include global economic conditions and macroeconomic, business and financial disruptions that could arise, including armed conflicts between Israel and Hamas (and potential broader military conflict in the region) and between Russia and Ukraine. There can be no assurance that a challenging economic environment or an economic downturn would not affect our liquidity or ability to obtain future financing or fund operations or investment opportunities. In addition, our debt covenants may restrict our ability to invest. Certain relevant measures of our liquidity and capital resources are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Change As of June 30 2025 2024 2023 2025 / 2024 2024 / 2023 ​ ​ (in thousands, except ratios) Cash and cash equivalents and short-term investments ​ $ 77,039 ​ $ 114,613 ​ $ 81,281 ​ $ (37,574) ​ $ 33,332 Working capital ​ 456,344 ​ 312,031 ​ 350,737 ​ 144,313 ​ (38,706) Ratio of current assets to current liabilities ​ 2.65:1 ​ 2.79:1 ​ 3.28:1 ​ ​ ​ We define working capital as total current assets (excluding cash and cash equivalents and short-term investments) less total current liabilities (excluding current portion of long-term debt). We calculate the ratio of current assets to current liabilities based on this definition. At June 30, 2025, we had $87.0 million in outstanding borrowings under the 2024 Credit Facilities. We had outstanding letters of credit and other commitments of $2.5 million, leaving $220.5 million available for borrowings and letters of credit, subject to restrictions in our 2024 Credit Facilities. We currently intend to pay quarterly dividends on our Class A and Class B common stock, subject to approval by the Board of Directors. Our Board of Directors has declared a cash dividend of $0.12 per share on Class A common stock and Class B common stock, payable on September 24, 2025 to stockholders of record at the close of business on September 3, 2025. Our future ability to pay dividends will depend upon our results of operations, financial condition, capital requirements, our ability to obtain funds from our subsidiaries and other factors that our Board of Directors deems relevant. Additionally, the terms of our current and any future agreements governing our indebtedness could limit our ability to pay dividends or make other distributions. 76 Table of Contents We do not expect to contribute to the domestic pension plan during 2026. At June 30, 2025, our cash and cash equivalents and short-term investments included $71.5 million held by our international subsidiaries. There are no restrictions on cash distributions to PAHC from our international subsidiaries. Contractual obligations Our contractual obligations include maturities under the 2024 Credit Facilities, including future interest accruals, and also operating lease commitments. See “Notes to Consolidated Financial Statements — Debt and Leases.” Off-balance sheet arrangements We currently do not use off-balance sheet arrangements for the purpose of credit enhancement, hedging transactions, investment or other financial purposes. In the ordinary course of business, we may indemnify our counterparties against certain liabilities that may arise. These indemnifications typically pertain to environmental matters. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to certain restrictions and limitations. 77 Table of Contents Selected Quarterly Financial Data (Unaudited) To facilitate quarterly comparisons, the following unaudited information presents the quarterly results of operations, including segment data, for the years ended June 30, 2025 and 2024. This quarterly financial data was prepared on the same basis as, and should be read in conjunction with, the audited consolidated financial statements and related notes included herein. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarters ​ Year ​ September 30,  December 31,  March 31,  June 30,  June 30,  For the Periods Ended ​ 2024 ​ 2024 ​ 2025 ​ 2025 ​ 2025 ​ ​ (in thousands) Net sales ​ ​ ​ ​ ​ MFAs and other ​ $ 107,844 ​ $ 150,338 ​ $ 181,645 ​ $ 206,527 ​ $ 646,354 Nutritional Specialties ​ 42,649 ​ 45,909 ​ 43,350 ​ 47,381 ​ 179,289 Vaccines ​ 32,030 ​ 33,171 ​ 33,382 ​ 38,570 ​ 137,153 Animal Health ​ $ 182,523 ​ $ 229,418 ​ $ 258,377 ​ $ 292,478 ​ $ 962,796 Mineral Nutrition ​ 59,062 ​ ​ 63,250 ​ ​ 66,774 ​ 64,154 ​ 253,240 Performance Products ​ 18,847 ​ ​ 16,593 ​ ​ 22,674 ​ 22,065 ​ 80,179 Total net sales ​ 260,432 ​ 309,261 ​ 347,825 ​ 378,697 ​ 1,296,215 Cost of goods sold ​ 176,937 ​ ​ 207,391 ​ ​ 243,257 ​ 268,688 ​ 896,273 Gross profit ​ 83,495 ​ 101,870 ​ 104,568 ​ 110,009 ​ 399,942 Selling, general and administrative expenses ​ ​ 65,796 ​ ​ 76,337 ​ ​ 71,053 ​ ​ 76,291 ​ ​ 289,477 Operating income ​ ​ 17,699 ​ ​ 25,533 ​ ​ 33,515 ​ ​ 33,718 ​ ​ 110,465 Interest expense, net ​ 7,641 ​ ​ 8,996 ​ ​ 9,355 ​ 8,610 ​ 34,602 Foreign currency losses (gains), net ​ 438 ​ ​ 11,699 ​ ​ (5,528) ​ 1,261 ​ 7,870 Income before income taxes ​ 9,620 ​ 4,838 ​ 29,688 ​ 23,847 ​ 67,993 Provision for income taxes ​ 2,645 ​ ​ 1,653 ​ ​ 8,808 ​ 6,623 ​ 19,729 Net income ​ $ 6,975 ​ $ 3,185 ​ $ 20,880 ​ $ 17,224 ​ $ 48,264 Net income per share ​ ​ ​ ​ ​ basic ​ $ 0.17 ​ $ 0.08 ​ $ 0.52 ​ $ 0.42 ​ $ 1.19 diluted ​ $ 0.17 ​ $ 0.08 ​ $ 0.51 ​ $ 0.42 ​ $ 1.19 Adjusted EBITDA ​ ​ ​ ​ ​ Animal Health ​ $ 40,385 ​ $ 58,177 ​ $ 63,123 ​ $ 60,575 ​ $ 222,260 Mineral Nutrition ​ 3,762 ​ 5,702 ​ 5,762 ​ 5,610 ​ 20,836 Performance Products ​ 2,288 ​ 1,888 ​ 3,336 ​ 3,035 ​ 10,547 Corporate ​ (15,779) ​ (17,592) ​ (17,335) ​ (19,253) ​ (69,959) Adjusted EBITDA ​ $ 30,656 ​ $ 48,175 ​ $ 54,886 ​ $ 49,967 ​ $ 183,684 Reconciliation of net income to Adjusted EBITDA ​ ​ ​ ​ ​ Net income ​ $ 6,975 ​ $ 3,185 ​ $ 20,880 ​ $ 17,224 ​ $ 48,264 Interest expense, net ​ 7,641 ​ 8,996 ​ 9,355 ​ 8,610 ​ 34,602 Provision for income taxes ​ 2,645 ​ 1,653 ​ 8,808 ​ 6,623 ​ 19,729 Depreciation and amortization ​ 9,004 ​ ​ 11,574 ​ ​ 12,616 ​ 12,411 ​ 45,605 EBITDA ​ ​ 26,265 ​ 25,408 ​ 51,659 ​ 44,868 ​ 148,200 Acquisition-related cost of goods sold ​ ​ — ​ ​ 1,634 ​ ​ 1,708 ​ ​ 2,337 ​ ​ 5,679 Acquisition-related transaction costs ​ ​ 3,424 ​ ​ 8,815 ​ ​ 636 ​ ​ 447 ​ ​ 13,322 Stock-based compensation ​ 179 ​ 180 ​ 179 ​ 179 ​ 717 Phibro Forward income growth initiatives implementation costs - cost of goods sold ​ ​ — ​ ​ — ​ ​ 3,798 ​ ​ — ​ ​ 3,798 Phibro Forward income growth initiatives implementation costs - SG&A ​ ​ 350 ​ ​ 1,696 ​ ​ 3,980 ​ ​ 952 ​ ​ 6,978 Insurance settlement gain ​ ​ — ​ ​ (1,257) ​ ​ (1,546) ​ ​ (77) ​ ​ (2,880) Foreign currency losses (gains), net ​ 438 ​ 11,699 ​ (5,528) ​ 1,261 ​ 7,870 Adjusted EBITDA ​ $ 30,656 ​ $ 48,175 ​ $ 54,886 ​ $ 49,967 ​ $ 183,684 ​ 78 Table of Contents ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quarters ​ Year ​ September 30,  December 31,  March 31,  June 30,  June 30,  For the Periods Ended ​ 2023 ​ 2023 ​ 2024 ​ 2024 ​ 2024 ​ ​ (in thousands) Net sales ​ ​ ​ ​ ​ MFAs and other ​ $ 94,104 ​ $ 101,941 ​ $ 108,216 ​ $ 116,698 ​ $ 420,959 Nutritional Specialties ​ 40,210 ​ 41,436 ​ 40,194 ​ 42,831 ​ 164,671 Vaccines ​ 26,216 ​ 29,727 ​ 32,923 ​ 31,986 ​ 120,852 Animal Health ​ $ 160,530 ​ $ 173,104 ​ $ 181,333 ​ $ 191,515 ​ $ 706,482 Mineral Nutrition ​ 56,026 ​ ​ 61,347 ​ ​ 64,228 ​ 62,062 ​ 243,663 Performance Products ​ 14,793 ​ ​ 15,492 ​ ​ 17,662 ​ 19,587 ​ 67,534 Total net sales ​ 231,349 ​ 249,943 ​ 263,223 ​ 273,164 ​ 1,017,679 Cost of goods sold ​ 163,623 ​ ​ 171,327 ​ ​ 183,623 ​ 186,014 ​ 704,587 Gross profit ​ 67,726 ​ 78,616 ​ 79,600 ​ 87,150 ​ 313,092 Selling, general and administrative expenses ​ ​ 68,452 ​ ​ 62,915 ​ ​ 59,676 ​ ​ 68,734 ​ ​ 259,777 Operating (loss) income ​ ​ (726) ​ ​ 15,701 ​ ​ 19,924 ​ ​ 18,416 ​ ​ 53,315 Interest expense, net ​ 4,564 ​ ​ 4,659 ​ ​ 4,575 ​ 4,738 ​ 18,536 Foreign currency losses, net ​ 6,689 ​ ​ 7,477 ​ ​ 2,427 ​ 7,270 ​ 23,863 (Loss) income before income taxes ​ (11,979) ​ 3,565 ​ 12,922 ​ 6,408 ​ 10,916 Benefit (provision) for income taxes ​ (3,964) ​ ​ 2,291 ​ ​ 4,517 ​ 5,656 ​ 8,500 Net (loss) income ​ $ (8,015) ​ $ 1,274 ​ $ 8,405 ​ $ 752 ​ $ 2,416 Net (loss) income per share ​ ​ ​ ​ ​ basic ​ $ (0.20) ​ $ 0.03 ​ $ 0.21 ​ $ 0.02 ​ $ 0.06 diluted ​ $ (0.20) ​ $ 0.03 ​ $ 0.21 ​ $ 0.02 ​ $ 0.06 Adjusted EBITDA ​ ​ ​ ​ ​ Animal Health ​ $ 28,494 ​ $ 39,299 ​ $ 36,524 ​ $ 41,289 ​ $ 145,606 Mineral Nutrition ​ 2,881 ​ 3,507 ​ 4,665 ​ 5,396 ​ 16,449 Performance Products ​ 1,409 ​ 817 ​ 2,371 ​ 3,065 ​ 7,662 Corporate ​ (14,133) ​ (14,171) ​ (13,856) ​ (16,320) ​ (58,480) Adjusted EBITDA ​ $ 18,651 ​ $ 29,452 ​ $ 29,704 ​ $ 33,430 ​ $ 111,237 Reconciliation of net (loss) income to Adjusted EBITDA ​ ​ ​ ​ ​ Net (loss) income ​ $ (8,015) ​ $ 1,274 ​ $ 8,405 ​ $ 752 ​ $ 2,416 Interest expense, net ​ 4,564 ​ 4,659 ​ 4,575 ​ 4,738 ​ 18,536 Provision for income taxes ​ (3,964) ​ 2,291 ​ 4,517 ​ 5,656 ​ 8,500 Depreciation and amortization ​ 8,871 ​ ​ 8,910 ​ ​ 9,196 ​ 9,201 ​ 36,178 EBITDA ​ ​ 1,456 ​ 17,134 ​ 26,693 ​ 20,347 ​ 65,630 Acquisition-related cost of goods sold ​ ​ — ​ ​ 310 ​ ​ 211 ​ ​ — ​ ​ 521 Acquisition-related transaction costs ​ ​ — ​ ​ — ​ ​ 512 ​ ​ 5,893 ​ ​ 6,405 Pension settlement cost ​ ​ 10,425 ​ ​ 249 ​ ​ — ​ ​ — ​ ​ 10,674 Brazil employment taxes ​ ​ — ​ ​ 4,202 ​ ​ — ​ ​ — ​ ​ 4,202 Stock-based compensation ​ ​ 81 ​ 80 ​ 135 ​ 179 ​ ​ 475 Phibro Forward income growth initiatives implementation costs - SG&A ​ ​ — ​ ​ — ​ ​ — ​ ​ 366 ​ ​ 366 Insurance proceeds ​ ​ — ​ ​ — ​ ​ (274) ​ ​ (625) ​ ​ (899) Foreign currency losses, net ​ ​ 6,689 ​ 7,477 ​ 2,427 ​ 7,270 ​ ​ 23,863 Adjusted EBITDA ​ $ 18,651 ​ $ 29,452 ​ $ 29,704 ​ $ 33,430 ​ $ 111,237 ​ ​ 79 Table of Contents General description of non-GAAP financial measures Adjusted EBITDA Adjusted EBITDA is an alternative view of performance used by management as our primary operating measure, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted EBITDA to reflect the results of our operations prior to considering certain income statement elements and to make financial and operating decisions. We calculate EBITDA as net income plus (i) interest expense, net, (ii) provision for income taxes or less benefit for income taxes and (iii) depreciation and amortization. We calculate Adjusted EBITDA as EBITDA plus (a) other expense or less other income, as separately reported on our consolidated statements of operations, including foreign currency (gains) losses, net and (b) certain items that we consider to be unusual, non-operational or non-recurring. The Adjusted EBITDA measure is not, and should not be viewed as, a substitute for GAAP reported net income and should not be viewed as a measure of liquidity. The Adjusted EBITDA measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how our Adjusted EBITDA measure is utilized: ● senior management receives a monthly analysis of our operating results that is prepared on an Adjusted EBITDA basis; ● our annual budgets are prepared on an Adjusted EBITDA basis; and ● other goal-setting and performance measurements are prepared on an Adjusted EBITDA basis. Despite the importance of this measure to management in goal setting and performance measurement, Adjusted EBITDA is a non-GAAP financial measure that has no standardized meaning prescribed by GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted EBITDA, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted EBITDA is presented to permit investors to more fully understand how management assesses performance. We also recognize that, as an internal measure of performance, the Adjusted EBITDA measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the Adjusted EBITDA measure is that it provides a view of our operations without including all events during a period, such as the depreciation of property, plant and equipment or amortization of acquired intangibles, and does not provide a comparable view of our performance to other companies. Adjusted net income and adjusted diluted earnings per share Adjusted net income and adjusted diluted earnings per share represent alternative views of performance and we believe investors’ understanding of our performance is enhanced by disclosing these performance measures. We report adjusted net income and adjusted diluted earnings per share to portray the results of our operations prior to considering certain income statement elements. We calculate adjusted net income as net income plus (i) acquisition-related intangible amortization and other acquisition-related items, (ii) certain items we consider to be unusual, non-operational or non-recurring, (iii) stock-based compensation expense, (iv) foreign currency (gains) losses, as separately reported on our consolidated statements of operations, and (v) the income tax effect of pre-tax income adjustments and certain income tax items. Adjusted diluted earnings per share is calculated using the adjusted net income divided by the diluted weighted average number of shares. The adjusted net income and adjusted diluted earnings per share measures are not, and should not be viewed as, a substitute for GAAP reported net income. Adjusted net income and adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of its non-standardized definition, adjusted net income and adjusted diluted earnings per share, unlike GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted net income and adjusted diluted earnings per share are presented to permit investors to more fully understand how management assesses performance. 80 Table of Contents Certain significant items Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share are calculated prior to considering acquisition-related items and certain other items, as detailed in the table titled “Items Excluded from Adjusted Net Income” above. We evaluate such items on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual or non-operational or non-recurring nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. We consider acquisition-related activities and business restructuring costs related to productivity and cost saving initiatives to be unusual items that we do not expect to occur as part of our normal business on a regular basis. We consider foreign currency gains and losses to be non-operational because they arise principally from intercompany transactions and are largely non-cash in nature. New accounting standards For discussion of new accounting standards, see “Notes to Consolidated Financial Statements — Summary of Significant Accounting Policies and New Accounting Standards.” Critical accounting policies Critical accounting policies are those that require application of management’s most difficult, subjective and/or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Not all accounting policies require management to make difficult, subjective or complex judgments or estimates. In presenting our consolidated financial statements in accordance with GAAP, we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results that differ from our estimates and assumptions could have an unfavorable effect on our financial position and results of operations. The following is a summary of accounting policies that we consider critical to the consolidated financial statements. Revenue Recognition We recognize revenue from product sales when control of the products has transferred to the customer, typically when title and risk of loss transfer to the customer. Certain of our businesses have terms where control of the underlying product transfers to the customer on shipment, while others have terms where control transfers to the customer on delivery. Revenue reflects the total consideration to which we expect to be entitled, in exchange for delivery of products or services, net of variable consideration. Variable consideration includes customer programs and incentive offerings, including pricing arrangements, rebates and other volume-based incentives. We record reductions to revenue for estimated variable consideration at the time we record the sale. Our estimates for variable consideration reflect the amount by which we expect variable consideration to affect the revenue recognized. Such estimates are based on contractual terms and historical experience and are adjusted to reflect future expectations as new information becomes available. Historically, we have not had significant adjustments to our estimates of customer incentives. Sales returns and product recalls have been insignificant and infrequent due to the nature of the products we sell. ​ 81 Table of Contents Business Combinations Our consolidated financial statements reflect the operations of an acquired business beginning as of the date of acquisition. Assets acquired and liabilities assumed are recorded at their fair values at the date of acquisition; goodwill is recorded for any excess of the purchase price over the fair values of the net assets acquired. Significant judgment may be required to determine the fair values of certain tangible and intangible assets and in assigning their respective useful lives. Significant judgment also may be required to determine the fair values of contingent consideration, if any. We typically utilize third-party valuation specialists to assist us in determining fair values of significant tangible and intangible assets and contingent consideration. The fair values are based on available historical information and on future expectations and assumptions deemed reasonable by management but are inherently uncertain. We typically use the direct cost, indirect cost and/or market approaches to measure the fair value of property, plant and equipment, as applicable, depending on the nature of the asset. Our estimates of the useful lives of such assets are based on a number of factors, including the asset’s age and condition at acquisition, the degree of technological or economic obsolescence, expected maintenance requirements, and the asset’s intended use within our operations. These estimates require significant management judgment and are based on historical experience with similar assets and independent valuations obtained at acquisition. We periodically review these estimates and adjust them prospectively when events or changes in circumstances indicate that a revision is warranted, which could materially affect depreciation expense in future periods. We typically use an income method to measure the fair value of intangible assets, based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect consideration of other marketplace participants and include the amount and timing of future cash flows, specifically the expected revenue growth rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances could affect the accuracy or validity of the estimates and assumptions. Determining the useful life of an intangible asset also requires judgment. Our estimates of the useful lives of intangible assets are primarily based on a number of factors including the competitive environment, underlying product life cycles, operating plans and the macroeconomic environment of the countries in which the products are sold. Intangible assets are amortized over their estimated lives. Intangible assets associated with acquired in-process research and development activities (“IPR&D”) are not amortized until a product is available for sale and regulatory approval is obtained. Long-Lived Assets and Goodwill We periodically review our long-lived and amortizable intangible assets for impairment and assess whether significant events or changes in business circumstances indicate that the carrying value of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset, a significant adverse change in the manner in which the asset is being used or in its physical condition or a history of operating or cash flow losses associated with the use of an asset. We recognize an impairment loss when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss is the excess of the asset’s carrying value over its fair value. In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would affect the amount of depreciation and amortization recorded in the consolidated statements of operations. Goodwill represents the excess of the purchase price over the fair value of the identifiable net assets acquired in a business combination. We assess goodwill for impairment annually during the fourth quarter, or more frequently if impairment indicators exist. Impairment exists when the carrying amount of goodwill exceeds its implied fair value. We may elect to assess our goodwill for impairment using a qualitative or a quantitative approach, to determine whether it is more likely than not that the fair value of goodwill is greater than its carrying value. ​ 82 Table of Contents Income Taxes The provision for income taxes includes U.S. federal, state and foreign income taxes and foreign withholding taxes. Our annual effective income tax rate is determined based on our income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which we operate and the tax impacts of items treated differently for tax purposes than for financial reporting purposes. Tax law requires certain items be included in the tax return at different times than the items are reflected in the financial statements. Some of these differences are permanent, such as expenses that are not deductible in our tax return, and some differences are temporary, reversing over time, such as depreciation expense. These temporary differences give rise to deferred tax assets and liabilities. Deferred tax assets generally represent the tax effect of items that can be used as a tax deduction or credit in future years for which we have already recorded the tax benefit in our income statement. Deferred tax liabilities generally represent the tax effect of items recorded as tax expense in our income statement for which payment has been deferred, the tax effect of expenditures for which a deduction has already been taken in our tax return but has not yet been recognized in our income statement or the tax effect of assets recorded at fair value in business combinations for which there was no corresponding tax basis adjustment. The recognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at the reporting date. Inherent in determining our annual effective income tax rate are judgments regarding business plans, planning opportunities and expectations about future outcomes. Realization of certain deferred tax assets, including research and development costs capitalized for income tax purposes and net operating loss carryforwards, is dependent upon generating sufficient future taxable income in the appropriate jurisdiction prior to the expiration of the amortization or carryforward periods. We establish valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. We may take tax positions that management believes are supportable but are potentially subject to successful challenge by the applicable taxing authority in the jurisdictions where we operate. We evaluate our tax positions and establish liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We account for income tax contingencies using a benefit recognition model. If our initial assessment does not result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit if: (i) there are changes in tax law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to “more likely than not”; (ii) the statute of limitations expires; or (iii) there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, and changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the “more-likely-than-not” standard. Our assessments concerning uncertain tax positions are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. Because there are a number of estimates and assumptions inherent in calculating the various components of our income tax provision, certain future events such as changes in tax legislation, geographic mix of earnings, completion of tax audits or earnings repatriation plans could have an impact on those estimates and our effective income tax rate. We expect to repatriate approximately $5.0 million of international earnings, which will be subject to applicable non-U.S. withholding and related taxes, net of reductions in U.S. income taxes. We intend to continue to reinvest indefinitely all other undistributed earnings of our foreign subsidiaries where we could be subject to applicable non-U.S. withholding and related taxes if amounts are repatriated to the U.S. For more information regarding our significant accounting policies, estimates and assumptions, see “Notes to Consolidated Financial Statements — Summary of Significant Accounting Policies and New Accounting Standards.” 83 Table of Contents Contingencies Legal matters We are subject to numerous contingencies arising in the ordinary course of business, such as product liability and other product-related litigation, commercial litigation, environmental claims and proceedings and government investigations. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid and/or accrued. We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Environmental Our operations and properties are subject to Environmental Laws and regulations. As such, the nature of our current and former operations exposes us to the risk of claims with respect to such matters, including fines, penalties and remediation obligations that may be imposed by regulatory authorities. Under certain circumstances, we might be required to curtail operations until a particular problem is remedied. Known costs and expenses under Environmental Laws incidental to ongoing operations, including the cost of litigation proceedings relating to environmental matters, are generally included within operating results. Potential costs and expenses may also be incurred in connection with the repair or upgrade of facilities to meet existing or new requirements under Environmental Laws or to investigate or remediate potential or actual contamination and from time to time we establish reserves for such contemplated investigation and remediation costs. In many instances, the ultimate costs under Environmental Laws and the time period during which such costs are likely to be incurred are difficult to predict. While we believe that our operations are currently in material compliance with Environmental Laws, we have, from time to time, received notices of violation from governmental authorities, and have been involved in civil or criminal action for such violations. Additionally, at various sites, our subsidiaries are engaged in continuing investigation, remediation and/or monitoring efforts to address contamination associated with historic operations of the sites. We devote considerable resources to complying with Environmental Laws and managing environmental liabilities. We have developed programs to identify requirements under, and maintain compliance with Environmental Laws; however, we cannot predict with certainty the impact of increased and more stringent regulation on our operations, future capital expenditure requirements, or the cost of compliance. The nature of our current and former operations exposes us to the risk of claims with respect to environmental matters and we cannot assure we will not incur material costs and liabilities in connection with such claims. Based upon our experience to date, we believe that the future cost of compliance with existing Environmental Laws, and liabilities for known environmental claims pursuant to such Environmental Laws, will not have a material adverse effect on our financial position, results of operations, cash flows or liquidity. For additional details, see “Business — Environmental, Health and Safety” and “Notes to Consolidated Financial Statements — Commitments and Contingencies.” ​ ​ ​ 84 Table of Contents